All News

Dr Buse’s in-depth review of the GRADE study is followed by a discussion of the keen need for more comparative research and the many new questions the results have raised about optimal T2D therapy.

ADA 2021. A subgroup analysis of the FIDELIO-DKD trial showed that finerenone use was beneficial regardless of baseline insulin use among patients with T2D and CKD.

Data from the Johns Hopkins COVID-19 interactive map and the CDC on COVID-19 vaccinations, cases, and deaths in the US and on cases and deaths worldwide.

Preliminary GRADE study results showed that liraglutide and insulin glargine added to metformin maintained A1c level in target range longer than glimepiride or sitagliptin.

ADA 2021. Dapagliflozin was found to reduce type 2 diabetes incidence among patients with chronic kidney disease in a prespecified analysis of the DAPA-CKD trial.

ADA 2021: The investigational exendin-4-based GLP-1 RA was associated with a 27% decrease in risk for a CV event and a 32% reduction in risk for CKD progression.

Data from the Johns Hopkins COVID-19 interactive map and the CDC on COVID-19 vaccinations, cases, and deaths in the US and on cases and deaths worldwide.

ADA 2021. A prespecified subanalysis of FIDELIO-DKD found primary and secondary renal and CV endpoints consistent whether or not GLP-1 receptor agonists were on board at study baseline.

ADA 2021. A prespecified subanalysis of FIDELIO-DKD found primary and secondary renal and CV endpoints consistent whether or not SGLT2 inhibitors were on board at study baseline.

Data from the Johns Hopkins COVID-19 interactive map and the CDC on COVID-19 vaccinations, cases, and deaths in the US and on cases and deaths worldwide.

Data released today at the American Diabetes Association 81st Scientific Sessions on a spike in new onset pediatric T2D at a single center during COVID-19 may signal much wider incidence.

Leading international diabetes researchers and clinicians will use the ADA's 81st annual Scientific Sessions as an ideal classroom to examine pandemic impact on diverse populations with diabetes.

Few common pain conditions have been as vexing to both patients and physicians as phantom limb pain. In our new slideshow, get a primer on prevention, treatment, pharmacotherapy, and more.

The upcoming ADA virtual 81st Scientific Sessions will feature 5 sessions on the latest diabetes developments learned during the initial phases of the COVID-19 pandemic.

Review of more than 300 clinical trials with products purported to facilitate weight loss found wide variability in risk of bias and data sufficiency suggesting caution among patients and physicians.

The novel Bigfoot Unity Diabetes Management System could help improve insulin dosing in patients with type 1 or type 2 diabetes.

Data from the Johns Hopkins COVID-19 interactive map and the CDC on COVID-19 vaccinations, cases, and deaths in the US and on cases and deaths worldwide.

It is critical for physicians to urge patients with obesity to get vaccinated against COVID-19 as they are one of the highest risk patient populations.